S
Stephen G. Reich
Researcher at Johns Hopkins University
Publications - 36
Citations - 4093
Stephen G. Reich is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Placebo & Progressive supranuclear palsy. The author has an hindex of 25, co-authored 36 publications receiving 3917 citations. Previous affiliations of Stephen G. Reich include Case Western Reserve University & University of Southampton.
Papers
More filters
Journal ArticleDOI
Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline.
Clifford W. Shults,David Oakes,Karl Kieburtz,M. Flint Beal,Richard H. Haas,Sandy Plumb,Jorge L. Juncos,John G. Nutt,Ira Shoulson,Julie H. Carter,Katie Kompoliti,Joel S. Perlmutter,Stephen G. Reich,Matthew B. Stern,Ray L. Watts,Roger Kurlan,Eric Molho,Madaline B. Harrison,Mark F. Lew +18 more
TL;DR: Coenzyme Q10 appears to slow the progressive deterioration of function in PD, but these results need to be confirmed in a larger study.
Journal ArticleDOI
Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease
J. James Frost,Annemie J. Rosier,Stephen G. Reich,Justin S. Smith,Michael D. Ehlers,Solomon H. Snyder,Hayden T. Ravert,Robert F. Dannals +7 more
TL;DR: The high specific/nonspecific binding ratio and the pronounced reduction in binding in mild PD may permit detection of even earlier stages of PD or presymptomatic individuals with dopaminergic cell loss.
Journal ArticleDOI
Practice Parameter: Diagnosis and prognosis of new onset Parkinson disease (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology
Oksana Suchowersky,Stephen G. Reich,J. Perlmutter,Theresa A. Zesiewicz,Gary S. Gronseth,William J. Weiner +5 more
TL;DR: Predictive factors for more rapid motor progression, nursing home placement, and shorter survival time include older age at onset of PD, associated comorbidities, presentation with rigidity and bradykinesia, and decreased dopamine responsiveness.
Journal ArticleDOI
Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease.
Iracema Leroi,Jason Brandt,Stephen G. Reich,Constantine G. Lyketsos,Stephen Grill,Richard E. Thompson,Laura Marsh +6 more
TL;DR: To evaluate the efficacy and safety of donepezil, an acetylcholinesterase inhibitor, as a treatment for cognitive impairment and dementia in patients with Parkinson' s disease (PD).
Journal ArticleDOI
Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease
Tatiana Foroud,Sean K. Uniacke,L. Liu,Nathan Pankratz,Anja Rudolph,Cheryl Halter,Clifford W. Shults,Karen Marder,P. M. Conneally,William C. Nichols,Lawrence I. Golbe,William C. Koller,Kelly E. Lyons,Frederick J. Marshall,David Oakes,Aileen Shinaman,Eric Siemers,Joanne Wojcieszek,Joann Belden,Julie H. Carter,Richard Camicioli,Pamela Andrews,Magali Fernandez,Jean P. Hubble,Carson Reider,Ali H. Rajput,Alex Rajput,Theresa Shirley,Michael Panisset,Jean Hall,Tilak Mendis,David Grimes,Peggy Gray,Carmen Serrano Ramos,Sandra Roque,Stephen G. Reich,Becky Dunlop,Robert A. Hauser,Juan Sanchez-Ramos,Theresa A. Zesiewicz,Holly Delgado,Joseph H. Friedman,Hubert H. Fernandez,Margaret C. Lannon,Lauren Seeberger,Christopher F. O'Brien,Deborah Judd,Lawrence Elmer,Kathy Davis,Deborah Fontaine,Ronald F. Pfeiffer,Brenda Pfeiffer,Michael J. Aminoff,Mariann DiMinno,Daniel D. Truong,Mayank Pathak,Anhoa Tran,Robert L. Rodnitzky,Judith Dobson,Rajesh Pahwa,Stephanie Thomas,Danna Jennings,Kenneth Marek,Susan Mendick,Juliette Harris,William J. Weiner,Roger Kurlan,Debra Berry,Peter A. LeWitt,Maryan DeAngelis,Paul J. Tuite,Robyn Schacherer,W.R. Wayne Martin,Marguerite Wieler,Bala V. Manyam,Patricia Simpson,John M. Bertoni,Carolyn Peterson,Mark Forrest Gordon,Joanna Hamann,Joseph Jankovic,Christine Hunter,Stewart A. Factor,Sharon Evans,Anette Nieves,Julie So,Mark Stacy,Kelli Williamson,Francis O. Walker,Victoria Hunt,Un Jung Kang,Shirley Uy,Karen Bindauer,Jeannine Petit,David Simon,Lisa Scollins,Rachel Saunders Pullman,Karyn Boyer,Paul Gordon +98 more
TL;DR: Mutations in the parkin gene occur among individuals with PD with an older age at onset (≥60 years) who have a positive family history of the disease, and the clinical findings of parkin-positive individuals are remarkably similar to those without mutations.